Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX,...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the...
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the...
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF)...
HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced...
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional...
HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development...
HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...